OVERVIEW

Advancing Specialty Pharmacy’s Role in the Multidisciplinary Approach to Managing Inflammatory Bowel Disease is organized by Pharmacy Times Continuing Education (PTCE).

Release Date: June 3, 2019
Expiration Date: June 3, 2020

Target audience:
Specialty Pharmacists and Managed Care Professionals.

Accreditation:
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs)

Program Description:
Inflammatory bowel disease (IBD) is compromised Crohn’s disease and ulcerative colitis. The advancement of treatment for IBD includes anti–TNF-α medications, integrin inhibitors, adhesion molecules, colony-stimulating factors, and others. Unlike traditional medications that tend to suppress the entire immune system, biologic therapies offer a targeted mechanism of action. It is critical to develop an individualized treatment plan that incorporates earlier use of immunosuppressants and biological therapy to minimize disease progression. Specialty pharmacists can help identify patients who have not responded to conventional therapy and who may benefit from other therapeutic options (ie, biological agents) by utilizing a cost-effective approach to optimize patients’ quality of life.

Educational Objectives:
Upon completion of this educational activity, participants will be able to:
• Identify the complications and quality of life issues related to uncontrolled IBD
• Compare current and emerging treatment options for IBD, including their safety and efficacy profiles
• Explore opportunities for specialty pharmacy intervention to improve patient outcomes in IBD

Additional details will be posted as soon as they are available.